Suvada, Kara; Plantinga, Laura; Vaughan, Camille P.; Markland, Alayne D.; Mirk, Anna; Burgio, Kathryn L.; Erni, Susanne M.; Ali, Mohammed K.; Okosun, Ike; Young, Henry; Goode, Patricia S.; Johnson, Theodore M. published the artcile< Comorbidities, Age, and Polypharmacy Limit the Use by US Older Adults with Nocturia of the Only FDA-approved Drugs for the Symptom>, Related Products of 94-20-2, the main research area is nocturia desmopressin acetate comorbidity polypharmacy aging United States; aged or elderly; comorbidity; medications; polypharmacy; risk factors; safety.
The goal of this study was to determine if the US adult population with nocturia (waking from sleep at night to void) can easily take medications (desmopressin acetate) approved by the US Food and Drug Administration for nocturia. Using a cross-sectional anal. of four US National Health and Nutrition Examination Survey (NHANES) waves (2005-2012), a total of 4111 participants aged ≥50 years who reported ≥2 nightly episodes of nocturia were identified. The main outcome was frequency of contraindications and drug interactions as described in US Food and Drug Administration-approved prescribing information. Desmopressin prescribing concerns were present in 80.5% (95% CI, 78.0-82.9) of those ≥50 years of age with nocturia; 50.0% (95% CI, 47.0-53.0) had contraindications, and 41.6% (95% CI, 39.3-44.0) took a concomitant drug that could increase risk of low serum sodium. Desmopressin contraindications were higher with older age (P < 0.001) and present in 73.2% (95% CI, 69.3-77.1) of those ≥80 years of age. This study showed that older US adults with nocturia have a high prevalence of medical conditions, concomitant medications, and baseline laboratory abnormalities that likely increase the risk of potentially severe adverse side effects from desmopressin use. A medication designed and approved for a clin. symptom that is most common in older adults could not be taken by most of the older adults with the symptom. Clinical Therapeutics published new progress about 5-HT reuptake inhibitors. 94-20-2 belongs to class amides-buliding-blocks, and the molecular formula is C10H13ClN2O3S, Related Products of 94-20-2.
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics